Please login to the form below

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

an asthma drug. ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) in patients with severe asthma without an eosinophilic phenotype.

Latest news

Pfizer, Sanofi and others set to increase US drug prices in 2021

Generic drugmaker Teva Pharmaceuticals has also raised the prices on 15 drugs, including rare neurological disorders drug Austedo (deutetrabenazine), asthma steroid Qvar (beclometasone) and more. ... One key tenet of Biden’s drug pricing pledge is to
Synairgen’s SNG001 advances into phase 3 COVID-19 trial

UK biotech had initially been testing drug for COPD and asthma. ... response. Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating SNG001’s potential in COVID-19
AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients. An experimental asthma drug co-developed by AstraZeneca (AZ) and Amgen significantly reduces the annualised asthma exacerbation rate (AAER) in patients ... asthma drug.
GSK seeks EU approval for Trelegy in adult asthma patients

The European Medicines Agency has accepted the regulatory submission for expanded use of GlaxoSmithKline’s Trelegy in adult asthma patients. ... Trelegy is a key drug in GSK’s arsenal, especially in its efforts to revive sales of its respiratory
Lilly expands dermatology portfolio with $1.1bn Dermira deal

Roche had been developing lebrikizumab as a potential treatment for severe asthma, but after the drug produced disappointing results in that indication decided to sell it on. ... If approved, Lilly’s newly acquired drug will closely compete with

More from news
Approximately 2 fully matching, plus 122 partially matching documents found.

Latest Intelligence

GSK forges ahead with its dynamic COPD and asthma portfolio

You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
The long and winding road to asthma breakthroughs

This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
Cancer immunotherapy: What's on the horizon?

Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
US health reforms

In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
Building BRICs: pharma's key emerging markets are becoming giants

In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Enterprise Therapeutics appoints CEO

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
Former RBS head takes the reins as GSK chair

the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....